
In latest AI Play, Sanofi Bets $630M+ for Formation Bio’s JAK/SYK Blocker
Sanofi has licensed gusacitinib, an oral JAK/SYK dual inhibitor from the “AI-native” drug development company Formation Bio, marking the pharma’s latest investment in AI-focused drug development. Terms of the deal, announced Monday, were sparse. The …